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ABSTRACT
Background: Iron deficiency anemia (IDA) is a common nutritional disease 
worldwide. Iron supplementation is an efficient method for treating patients with 
IDA. Polysaccharide iron complex is an oral iron supplement that is associated with 
generally good tolerability and good bioavailability.
Objective: The aim of this study was to evaluate the bioequivalence of 
2 branded formulations of polysaccharide iron complex in healthy adult male Chinese 
volunteers by determining the pharmacokinetic parameters after single-dose oral 
administration.
Methods: This sequence-randomized, double-blind, 2-way crossover study was 
carried out in the Affiliated Hospital, Institute of Medical Sciences of Qingdao Uni-
versity, Qingdao, China. Healthy adult male Chinese volunteers were enrolled and 
evenly randomized to receive 1 of 2 formulations on day 1. Subjects received an oral 
dose of 150 mg (1 capsule) of polysaccharide iron complex with 150 mL of warm 
water in the morning. Capsules were of similar size, shape, and color to ensure blind-
ing. Four hours after administration, the subjects were given standardized meals. 
After a 1-week washout period, the subjects were crossed over to receive the other 
formulation in a similar manner. The serum iron concentration 12 hours after study 
drug administration was determined using atomic-absorption spectrometry. The 
pharmacokinetic parameters Cmax, Tmax, AUC0–t, and AUC0–∞ were obtained and ana-
lyzed using the Schuirmann 2 one-sided t test. The 2 formulations were considered 
bioequivalent if the test/reference ratios of Cmax, AUC0–t, and their 90% CIs were within 
the range of 70% to 143% for Cmax and within 80% to 125% for AUC0–t. Tolerability 
was monitored by inquiring whether the subjects had experienced adverse events (AEs), 
with a focus on gastrointestinal AEs, during the clinic visits during the 24-hour period 
after drug administration and subsequently via telephone throughout the study.
Results: Thirty adult male Chinese volunteers were assessed for inclusion. 
Twenty healthy male volunteers (10 in each group) (mean [SD] age, 21.5 [2.9] years 
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[range, 19–23 years]; weight, 66.2 [5.8] kg [range, 56–80 kg]; height, 172.5 [5.1] cm 
[range, 162–180 cm]) were enrolled and completed the study. The pharmacokinetic 
parameters of the test and reference formulations were as follows: AUC0–t, 6.58 
(2.09) and 6.58 (1.91) μg/mL ⋅ h–1; Cmax, 1.10 (0.28) and 1.07 (0.25) μg/mL; Tmax, 
3.93 (0.37) and 3.93 (0.37) hours; t1/2, 8.33 (0.36) and 8.38 (0.41) hours; and 
AUC0–∞, 6.93 (2.23) and 6.95 (2.13) μg/mL ⋅ h–1, respectively. There were no statisti-
cally significant differences in AUC0–t or Tmax by formulation, period, or subject be-
tween the test and reference formulations. Similarly, there were no statistically 
significant differences in Cmax by period; however, a significant difference was found 
in Cmax by formulation (P = 0.012). No clinically significant AEs were reported with 
either formulation.
Conclusions: In these healthy adult male Chinese volunteers, the test formu-
lation of polysaccharide iron complex was found to be bioequivalent to the reference 
formulation according to the Chinese regulatory definition. A significant difference 
by formulation was found in Cmax. The sample size was smaller than that recom-
mended by the US Food and Drug Administration for a bioequivalence study, and 
additional studies with larger sample sizes are needed. (Curr Ther Res Clin Exp. 
2009;70:104–115) © 2009 Excerpta Medica Inc.
Key words: polysaccharide iron complex, Hongyuanda™, Niferex™, bio- 
equivalence, healthy male volunteers.
INTRODUCTION
Iron is important in many bodily functions, especially for the transport of oxygen in 
the blood.1 Iron deficiency anemia (IDA) is a common nutritional disease worldwide.2 
Using anemia as an indicator, the World Health Organization has estimated that 39% 
of the children 0 to 4 years of age in nonindustrialized countries and 20% of those in 
industrialized countries have iron deficiency.3 Iron supplementation is an efficient 
method for treating patients with IDA.4 Traditional iron supplements, such as ferrous 
sulfate, are associated with serious adverse events (AEs) including abdominal pain, 
heartburn, nausea, vomiting, constipation, and diarrhea, probably owing to produc-
tion of hydroxyl free radicals.5 Polysaccharide iron, a form of the mineral iron, is the 
complex of ferric iron and a low-molecular-weight polysaccharide. This polysaccha-
ride is produced by extensive hydrolysis of starch.6,7 As a ferric supplement, polysac-
charide iron has been used to prevent and to treat iron deficiencies and IDA in clinical 
practice.6,7 Polysaccharide iron can increase concentrations of serum iron and hemo-
globin.8,9 It also can be combined with other antianemia drugs, such as recombinant 
human erythropoietin, to reduce the degree of anemia.10,11 The absorption of polysac-
charide iron complex is comparable to that of a ferrous salt, but it has been associated 
with fewer gastrointestinal AEs.12,13 These clinical observations suggest that polysac-
charide iron complex, which is associated with generally good tolerability and good 
bioavailability, might be used as an oral iron supplement.14 Because polysaccharide 
iron is an organic complex without free ions, it may not be associated with AEs com-
mon to free ferrous ion: tension, diarrhea, motion sickness, and gastritis.4 Polysac-
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charide iron complex can be absorbed at the molecular level in the gastrointestinal 
tract, and its absorption is not affected by a reduction of hydrochloric acid in gastric 
fluids or by food.15 Therefore, polysaccharide iron complex may be regarded as a reli-
able, effective iron supplement.
According to the bioequivalence standards of the Chinese State Food and Drug 
Administration (SFDA),16 2 formulations are considered bioequivalent if the test/
reference ratios of Cmax, AUC0–t, and their 90% CIs are within the range of 70% to 
143% for Cmax and within 80% to 125% for AUC0–t. The bioequivalence standards 
of the SFDA are consistent with those of the US FDA.17 
The aim of this study was to evaluate the bioequivalence of 2 branded formulations 
of polysaccharide iron complex in Chinese volunteers by determining the pharmaco- 
kinetic parameters after single-dose oral administration.
SUBJECTS AND METHODS
Subjects
Healthy adult male volunteers were recruited via posters placed at a local university 
campus. Volunteers were selected after passing a clinical screening procedure that 
included a physical examination and laboratory tests (blood chemistry, urinalysis, and 
liver and kidney function studies). Exclusion criteria were a history of drug or alcohol 
abuse, allergy or AEs with iron therapy, and use of any other investigational medica-
tion within 1 month of enrollment. Volunteers were also excluded if they had a history 
of any illness of the gastrointestinal tract; hepatic, renal, neural, or cardiovascular 
systems; or a metabolic abnormality; or any other type of coexisting anemia. This was 
done to ensure that the existing degree of variation would not be due to an influence 
of illness or other medications.
The study was conducted according to the revised Declaration of Helsinki for bio-
medical research involving human subjects and the rules of Good Clinical Practice 
(China).18 Accordingly, subjects were informed of the aim and risks of the study by 
the clinical investigator. Subjects were free to withdraw at any time. All participants 
provided written informed consent after they had been informed of the nature and 
details of the study. Subjects were compensated for their participation. Investigators 
were paid their usual salaries and additional money for participating in this study.
Medications and Apparatus
A test formulation* (lot no. 070201; expiration date, July 2, 2009) and a reference 
formulation† (lot no. 109280507; expiration date, November 15, 2008) of polysac-
charide iron complex 150-mg capsules were studied. Formulations used were of simi-
lar size, shape, and color to ensure blinding. 
Iron criteria solution (National Steel Material Test Center, Beijing, China; 1000 μg/mL 
in 10% hydrochloric acid) and blood serum standard samples (standard calf serum, 
*Trademark: Hongyuanda™ (Guofeng Pharmaceutical Co., Ltd., Qingdao, China).
†  Trademark: Niferex™ (Central Pharmaceuticals, Inc., Seymour, Indiana).
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National Standard Substance Research Center, Beijing, China) were used. The mean 
(SD) iron content of the standard serum samples was 1.57 (0.22) μg/mL. 
An atomic-absorption spectroscopy (AAS) spectrometer (model AA7003, East & 
West Analytical Instruments, Inc., Beijing, China) was used for analysis (wavelength, 
248.33 nm). 
Study Design
This sequence-randomized, double-blind, 2-way crossover study was carried out in 
the Affiliated Hospital, Institute of Medical Sciences of Qingdao University, Qingdao, 
China. The study protocol was approved by the institutional review board of the In-
stitute of Medical Sciences of Qingdao University.
Each subject received 1 of 2 formulations of an oral dose of 150 mg (1 capsule) of 
polysaccharide iron complex on the morning of day 1. A pseudorandomization test 
was done according to the randomization table pregenerated using SAS software ver-
sion 8.0 (SAS Institute Inc., Cary, North Carolina). The capsules were taken in the 
morning with 150 mL of warm water. Four hours after administration, all subjects 
were given standardized meals (2500 kcal). After a 1-week washout period, the sub-
jects were crossed over to the other formulation, in a similar manner. All subjects were 
instructed to refrain from smoking and from consumption of beverages containing 
alcohol or coffee, carbonated beverages, syrup, and foods containing large amounts of 
iron during the study period. 
Subjects were instructed to report if they had experienced rheum or bacterial infec-
tion at any time during the study. Subjects who experienced rheum or bacterial infec-
tion during the study were to be withdrawn. Clinical investigators examined the 
subjects during the 24-hour period after drug administration and subsequently via 
telephone throughout the study. 
Blood Sample Collection
Five-milliliter blood samples were collected via an indwelling cannula from the 
median cubital vein at 0, 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 9, and 12 hours after study 
drug administration. The blood samples were withdrawn into heparinized glass tubes 
(Vacutainer, Heraeus, Hanau, Germany) and were stored for 30 minutes in water at 
37°C. The blood samples were centrifuged at 3000 rpm for 5 minutes at 4°C, and a 
2-mL aliquot of each sample was collected and stored frozen at −20°C until AAS 
analysis.
Iron Content Assay
Each serum sample was diluted with 0.15% deionized water solution (Triton™ X-100, 
The Dow Chemical Company, Midland, Michigan) at a ratio of 1:3, as explained 
further. The iron concentration in each sample was analyzed using an AAS meth-
od.19 The serum samples were diluted before AAS analysis to reduce the viscosity 
to a level that could be tested using AAS. To identify the optimum dilution ratio, 
iron concentrations in the serum samples were tested at ratios of 1:3, 1:4, 1:9, and 
1:10. Five duplicate tests were carried out at each dilution ratio. F and t tests were 
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used to determine the differences in iron concentration at the different dilution 
ratios.
Precision (intraday and interday) tests were carried out at nominal iron concentra-
tions of 0.2, 0.5, and 0.9 μg/mL. Recovery experiments were done at nominal iron 
concentrations of 0.2, 0.4, and 0.9 μg/mL. The standard curve of the serum was es-
tablished using standard calf serum.
Methodology
Because the viscidity of serum is too high to assay iron content by AAS analysis, it 
was necessary to reduce the viscidity by diluting with deionized water and surfactant, 
such as Triton X-100. The F test (α = 0.05) indicated that there were no significant 
differences in iron content between the data groups with different dilution ratios (1:3, 
1:4, 1:9, and 1:10, respectively). The t test (α = 0.05) found that there were signifi-
cant differences in serum iron concentration between the dilution ratios of 1:3 or 1:4 
and the other dilution ratios when the serum samples were diluted by deionized wa-
ter; no significant differences were found between the dilution ratios of 1:3, 1:4, and 
the other dilution ratios when the serum samples were diluted by deionized water 
containing Triton X-100 (0.15%, W/W). According to the results of the F and 
t tests, the optimum dilution ratio of the serum samples was 1:3 with deionized water 
containing Triton X-100 (0.15%, W/W); therefore, the above optimum dilution ratio 
was used in testing.
Under the described analytical conditions, the lower limit of quantification (LLOQ) 
for polysaccharide iron was 0.2 μg/mL. The relationship between the concentration 
and peak area ratio was shown to be linear from 0.05 to 2.0 μg/mL (r > 0.998) (n = 
5), and was represented as the following equation: 
Y = 9.2491X,
where Y was the iron content of the serum and X was the amount of absorption of 
light. 
Quality control samples used to evaluate interassay and intra-assay precision were 
prepared by spiking control human serum with 0.2 (LLOQ), 0.5, and 0.8 μg/mL of 
iron.
The intraday precision ranged from 2.03% to 6.33% (all, relative standard devia-
tion [RSD] < 15%), while the interday precision ranged from 1.88% to 6.15% (all, 
RSD < 15%) (n = 15). Recovery was in the range of 85% to 115% (n = 15) when the 
concentration was 0.2, 0.4, and 0.9 μg/mL.
Tolerability Assessment
Tolerability was monitored by inquiring whether the subjects had experi- 
enced any AEs, but especially gastrointestinal AEs, during the clinic visits during 
the 24-hour period after drug administration and subsequently via telephone 
throughout the study. Subjects were followed up for one week after the second 
administration. 
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The severity of the symptoms was assessed using the Treatment Emergent Symp-
toms Scale (scale: 0 = absent; 1 = slight; 2 = mild; 3 = moderate; and 4 = severe).20
Statistical Analysis
All statistical analyses were performed using the CRFB Bioavailability Statistical 
Program (Mathematics and Pharmacology Institute, Beijing, China). The data analysis 
plan was developed a priori. AUC0–t was calculated using the trapezoidal method. Cmax 
and Tmax were obtained directly from the serum concentration–time curves of iron.
AUC0–t, Tmax, and Cmax were considered to be the primary end points to assess the 
bioequivalence between the test and reference formulations. Analysis of variance 
(ANOVA) (α = 0.1) using logarithmically transformed AUC0–t, Cmax, and Tmax for the 
randomized 2-way crossover design was used to assess the effect of formulation, peri-
od, and subject on these parameters.21 The 2 formulations were considered bioequiva-
lent if the test/reference ratios of Cmax, AUC0–t, and their 90% CIs were within 70% 
to 143% for Cmax and within 80% to 125% for AUC0–t.
16 
Differences between 2 related parameters were considered statistically significant 
at P ≤ 0.05. The Schuirmann 2 one-sided t test for logarithmically transformed data 
was conducted to test the bioequivalence of the pharmacokinetic characteristics of 
the 2 formulations.
RESULTS
Subjects
Thirty volunteers were assessed for inclusion. Twenty healthy adult male Chinese 
volunteers (10 in each group) (mean [SD] age, 21.5 [2.9] years [range, 19–23 years]; 
weight, 66.2 [5.8] kg [range, 56–80 kg]; height, 172.5 [5.1] cm [range, 162–180 cm]) 
were enrolled and completed the study. The demographic characteristics of the sub-
jects are shown in Table I.
Pharmacokinetic Characteristics
AEs were measured individually through evaluation of the following 6 adverse 
gastrointestinal events: abdominal pain, heartburn, nausea, vomiting, constipation, 
and diarrhea. The clinical measurement was the proportion of subjects who reported 
Table I.  Demographic characteristics of healthy male Chinese volunteers (N = 20).* Data 
are mean (SD).
 Test Formulation† Reference Formulation‡ 
Characteristic  (n = 10)  (n = 10)
Age, y 20.4 (1.0) 21.2 (10.3)
Height, cm 172.3 (4.2) 171.3 (4.1)
Weight, kg 56.2 (5.5) 63.4 (6.0)
*No significant between-group differences were found.
†Trademark: Hongyuanda™ (Guofeng Pharmaceutical Co., Ltd., Qingdao, China).
‡Trademark: Niferex™ (Central Pharmaceuticals, Inc., Seymour, Indiana).
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any AE (gastrointestinal or otherwise). Clinical tolerability was good for both formu-
lations. No clinically relevant AEs occurred during or after the study.
At the first sampling time (1 hour) after study drug administration, mean (SD) 
serum iron concentration was detectable in both the test and reference groups (test, 
0.20 [0.08] μg/mL; reference, 0.23 [0.11] μg/mL) (Figure 1). The mean (SD) Tmax for 
the test and reference formulations were both 3.93 (0.37) hours and Cmax was 1.10 (0.28) 
and 1.07 (0.25) μg/mL, respectively. No statistically significant differences in these 2 pa-
rameters were found between the 2 formulations. Serum iron concentrations then gradu-
ally declined, with a mean (SD) terminal t1/2 of 8.33 (0.36) hours and 8.38 (0.41) hours 
for the test and reference formulations, respectively (Figure 1 and Table II).
The bioavailability parameters AUC0–t, Cmax, and Tmax of the polysaccharide iron 
complexes were obtained and compared by noncompartmental model analysis. The 
mean AUC0–t values were similar for the test and reference formulations (6.58 [2.09] 
and 6.58 [1.91] μg/mL ⋅ h–1, respectively), and the mean AUC0–∞ values were also 
similar (6.93 [2.23] and 6.95 [2.13] μg/mL ⋅ h–1) (Table II). The relative bioavaila- 
bility of the test formulation to the reference formulation was 101.0%.
Standard Bioequivalence Analysis
The results of the ANOVA test for AUC0–t, Cmax, and Tmax are shown in Table III. 
No statistically significant formulation, period, or subject effects were found in 
1.2
0.8
0.4
0
0.2
102 84 126
Time After Study Drug Administration (h)
M
ea
n 
S
er
um
 Ir
on
C
on
ce
nt
ra
tio
n 
(μ
g/
m
L)
0
1.0
0.6
Test
Reference
Figure 1.  Mean serum concentration–time profiles after administration of a single oral 
dose (150 mg) of test (Hongyuanda™ [Guofeng Pharmaceutical Co., Ltd., 
Qingdao, China]) and reference (Niferex™ [Central Pharmaceuticals, Inc., Sey-
mour, Indiana]) formulations of polysaccharide iron complex in healthy adult 
male Chinese volunteers.
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AUC0–t or Tmax. A statistically significant formulation effect was found in Cmax (P = 
0.012); the effects of period were not significant.
The 90% CIs of AUC0–t, Cmax, and Tmax (natural-log transformed) were 0.986 to 
1.031, 0.964 to 0.992, and 0.999 to 1.000, respectively (Table IV). The differences 
between AUC0–t, Tmax, and Cmax were not significant.
Dissolution Rate
Figure 2 shows the dissolution rates of test and reference formulations. The test 
formulation was completely dissolved at 25 minutes with a dissolution rate of 
100.67%, while the reference drug was not completely dissolved until 40 minutes. 
DISCUSSION
In this study of 20 healthy male Chinese subjects, two 150-mg polysaccharide iron 
complex formulations were found to be bioequivalent in all the pharmacokinetic pa-
rameters except Cmax when analyzed using ANOVA.
Table II.  Bioavailability parameters after administration of test and reference formula-
tions of polysaccharide iron complex in healthy male Chinese volunteers (N = 
20).* Data are mean (SD).
 Test Formulation† Reference Formulation‡ 
Parameter  (n = 10) (n = 10)
AUC0–t, μg/mL ⋅ h–1 6.58 (2.09) 6.58 (1.91)
Cmax, μg/mL 1.10 (0.28) 1.07 (0.25)
Tmax, h 3.93 (0.37) 3.93 (0.37)
MRT0–t, h 5.35 (0.17) 5.39 (0.19)
t1/2, h 8.33 (0.36) 8.38 (0.41)
MRT0–∞, h 5.85 (0.34) 5.89 (0.40)
AUC0–∞, μg/mL ⋅ h–1 6.93 (2.23) 6.95 (2.13)
MRT = mean residence time. 
*No significant between-group differences were found.
†Trademark: Hongyuanda™ (Guofeng Pharmaceutical Co., Ltd., Qingdao, China).
‡Trademark: Niferex™ (Central Pharmaceuticals, Inc., Seymour, Indiana).
Table III.  Analysis of variance test (α = 0.1) for natural–log-transformed AUC0–t, Cmax, 
and Tmax in healthy male Chinese volunteers (N = 20).
Source of Variance AUC0–t P* Cmax P* Tmax P*
Formulation 0.001 0.521 0.005 0.012 <0.001 0.331
Period 0.001 0.548 0.002 0.073 <0.001 0.331
Subject 3.567 <0.001 2.298 <0.001 5.275 <0.001
*F test.
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Clinical tolerability was good with both formulations. Almost identical serum iron 
concentration profiles were obtained with both formulations. Both formulations ap-
peared to be readily absorbed in the gastrointestinal tract; measurable concentrations 
of polysaccharide iron were present at the first sampling time (1 hour postadministra-
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Figure 2.  Dissolution rate curve of a single oral dose (150 mg) of test (Hongyuanda™ 
[Guofeng Pharmaceutical Co., Ltd., Qingdao, China]) and reference (Niferex™ 
[Central Pharmaceuticals, Inc., Seymour, Indiana]) formulations of polysaccharide 
iron complex in deionized water at 37°C in healthy adult male Chinese volunteers.
Table IV.  Results of the Schuirmann 2 one-sided t tests on pharmacokinetic parameters 
of healthy adult male Chinese volunteers who received a single-dose adminis-
tration of 2 formulations of polysaccharide iron complex (N = 20).
Parameter AUC0–t Cmax Tmax
Test,* mean  1.844  0.045  3.925
Reference,† mean  1.835  0.067  3.925
Mean error  0.041  0.025  0.007
t‡  1.734  1.734  1.734
t1 17.929 24.929 351.063
t2 16.606 30.502 351.063
90% CI 0.986–1.031 0.964–0.992 0.999–1.000
*Trademark: Hongyuanda™ (Guofeng Pharmaceutical Co., Ltd., Qingdao, China).
†  Trademark: Niferex™ (Central Pharmaceuticals, Inc., Seymour, Indiana).
‡  α = 0.05, df = 18. 
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tion) in all subjects. Serum profiles of polysaccharide iron concentration versus time 
after the oral administration of a single dose of both formulations exhibited similar 
patterns. All of the bioavailability parameters studied (AUC0–t, Cmax, Tmax, t1/2, and 
AUC0–∞) were found to be similar for the 2 formulations. No significant difference 
was found between the 2 formulations in AUC0–t or Tmax using ANOVA; however, a 
significant difference was found in Cmax by formulation (P = 0.012).
With regard to dissolution rates, the test formulation was completely dissolved at 
25 minutes, while the reference formulation was completely dissolved at 40 minutes; 
significant differences were found in dissolution rates between test and reference for-
mulations. Although the test formulation had a more rapid dissolution than that of 
the reference formulation, bioavailability was equivalent between the 2 formulations. 
This implies that the dissolution rate has little influence on the bioavailability of the 
formulations. This may be caused by the differing composition and preparation tech-
niques of the formulations.
No clinically relevant AEs were reported during or after the study. Both formula-
tions were well tolerated; no patient withdrew from the study due to an AE. This 
finding coincides with the findings of another study that a ferric polysaccharide prod-
uct was associated with fewer AEs than a ferrous product.9 Ferrous products, such as 
ferrous sulfate, are associated with serious AEs.5 The 90% CIs for AUC0–t were com-
pletely contained within the predefined bioequivalence acceptance range of 80% to 
125%. Bioequivalence was also demonstrated for Cmax, with the 90% CI within the 
range of 70% to 143%. These findings both meet the standards required by the SF-
DA.16 However, a statistically significant difference was found by formulation in Cmax 
(P = 0.012). 
This difference in Cmax has less effect on bioequivalence between the 2 formulations 
than AUC0–t. For iron supplementation therapy, AUC0–t is more important than Cmax 
because it is more indicative of the serum iron content on which the effectiveness of 
iron supplementation depends.22 Moreover, the iron absorbed after dosing is less 
closely related to Cmax than to AUC0–t. This relationship is different from that of other 
drugs (eg, antibiotics) whose Cmax determines whether the drug concentration reaches 
therapeutic levels.23 A statistically significant between-formulation difference was not 
found in AUC0–t. Therefore, the 2 formulations were considered bioequivalent despite 
a significant difference in Cmax by formulation.
All pharmacokinetic parameters derived using the noncompartmental method 
were found to be similar for both formulations. The oral polysaccharide iron complex 
was cleared from the serum with a t1/2 of ~8.33 and 8.38 hours for the test and refer-
ence formulations, respectively, which were in accordance with published results for 
polysaccharide iron complex.23
According to SFDA guidance for bioavailability and bioequivalence studies for chemi-
cal drug products in humans,21 a sample size of 18 to 24 subjects is sufficient for a 
bioequivalence study. The sample size used in this study (20 subjects) had a power of 90% 
to detect a scientifically meaningful difference in AUC0–t between the 2 formulations.
24
Based on the US FDA guidelines, the sample size used in this study was smaller 
than that recommended for a bioequivalence study.17 Therefore, the results of the 
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present study require further confirmation by larger studies. Additional limitations of 
this study were the use of only a single dose of polysaccharide iron complex and the 
fact that all the subjects were healthy volunteers.
CONCLUSIONS
In these healthy male Chinese volunteers, the test formulation of polysaccharide iron 
complex was found to be bioequivalent to the reference formulation according to the 
Chinese regulatory definition. A significant difference by formulation was found in 
Cmax. The sample size was smaller than that recommended by the US FDA for a 
bioequivalence study, and additional studies with larger sample sizes are needed.
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